menu
    • menu
    [{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axon Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Axon Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"University of California, San Francisco | Massachusetts General Hospital | Alzheimer's Therapeutic Research Institute | Alzheimer's Clinical Trials Consortium | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CYPRUS","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"AADvac1","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axon Neuroscience \/ University of California, San Francisco | Massachusetts General Hospital | Alzheimer's Therapeutic Research Institute | Alzheimer's Clinical Trials Consortium | National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuroscience \/ University of California, San Francisco | Massachusetts General Hospital | Alzheimer's Therapeutic Research Institute | Alzheimer's Clinical Trials Consortium | National Institute on Aging"}]

    Find Clinical Drug Pipeline Developments & Deals by Axon Neuroscience

    Menu

    Axon Neuroscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : University of California, San Francisco | Massachusetts General Hospital | Alzheimer's Therapeutic Research Institute | Alzheimer's Clinical Trials Consortium | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alzheimer's Tau Platform: Regimen A - AADvac1

                            Details : AADvac1 is a Vaccine drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 11, 2025

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : University of California, San Francisco | Massachusetts General Hospital | Alzheimer's Therapeutic Research Institute | Alzheimer's Clinical Trials Consortium | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AXON Neuroscience Presented Results from its Phase II Clinical Trial Showing Multifold Therapeutic Effect of i...

                            Details : Axon is developing AADvac1 as a vaccine with the potential to halt the progression of tau pathology in Alzheimer's disease. AADvac1 is currently the most clinically-advanced tau immonotherapy in development.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 01, 2021

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Peptide Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development

                            Details : Axon used its established peptide-based vaccine platform to produce a novel prophylactic COVID-19 vaccine, intended to treat infected patients and protect healthy individuals from infection.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 09, 2020

                            Lead Product(s) : COVID-19 Peptide Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020

                            Details : A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 03, 2020

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia

                            Details : AADvac1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Primary Progressive Nonfluent Aphasia.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 05, 2017

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

                            Details : AADvac1 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 19, 2015

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

                            Details : AADvac1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 09, 2014

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Axon Neuroscience

                            Cyprus arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

                            Details : AADvac1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 09, 2013

                            Lead Product(s) : AADvac1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth